Abstract
Previous studies have related early postnatal growth with later lung function but their interpretation is limited by the methods used to assess a child's growth. We aimed to assess the association of early childhood growth, measured by body mass index (BMI) trajectories up to 4 years, with lung function at 7 years.
We included 1257 children from the Spanish Infancia y Medio Ambiente population-based birth cohort. Early childhood growth was classified into five categories based on BMI trajectories up to 4 years previously identified using latent class growth analysis. These trajectories differed in birth size (“lower”, “average”, “higher”) and in BMI gain velocity (“slower”, “accelerated”). We related these trajectories to lung function (forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/ FVCand forced expiratory flow at 25%–75% of FVC (FEF25 - 75%)) at 7 years, using multivariable mixed regression.
Compared to children with average birth size and slower BMI gain (reference), children with higher birth size and accelerated BMI gain had a higher FVC % pred (3.3%, 95% CI 1.0%–5.6%) and a lower FEV1/ FVC% pred (−1.5%, 95% CI −2.9%–−0.1%) at 7 years. Similar associations were observed for children with lower birth size and accelerated BMI gain. Children with lower birth size and slower BMI gain had lower FVC % pred at 7 years. No association was found for FEF25 - 75%.
Independently of birth size, children with accelerated BMI gain in early childhood had higher lung function at 7 years but showed airflow limitation. Children with lower birth size and slower BMI gain in early childhood had lower lung function at 7 years.
Abstract
Independently of birth size, children with accelerated BMI gain in early childhood had higher lung function at 7 years but showed airflow limitation. Children with lower birth size and slower BMI gain in early childhood had lower lung function at 7 years.https://bit.ly/308ZDtn
Footnotes
This article has supplementary material available fromwww.qdcxjkg.com
Author contributions: G.P. Peralta, M. Casas and J. Garcia-Aymerich designed the study. G.P. Peralta conducted the statistical analyses and wrote the initial draft. M. Casas and J. Garcia-Aymerich had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors provided substantial contributions to the conception or design of the work or the acquisition, analysis or interpretation of data for the work, revised the manuscript for important intellectual content, approved the final version and agreed to be accountable for all aspects of the work.
Conflict of interest: G.P. Peralta has nothing to disclose.
Conflict of interest: A. Abellan has nothing to disclose.
Conflict of interest: P. Montazeri has nothing to disclose.
Conflict of interest: M. Basterrechea has nothing to disclose.
Conflict of interest: A. Esplugues has nothing to disclose.
Conflict of interest: S. González-Palacios has nothing to disclose.
Conflict of interest: C. Roda has nothing to disclose.
Conflict of interest: L. Santa-Marina has nothing to disclose.
Conflict of interest: J. Sunyer has nothing to disclose.
Conflict of interest: M. Vrijheid has nothing to disclose.
Conflict of interest: M. Casas has nothing to disclose.
Conflict of interest: J. Garcia-Aymerich reports personal fees for lectures from Esteve and Chiesi, and institutional fees for lectures and consultancy from AstraZeneca, outside the submitted work.
Support statement: This study was funded by grants from the EU (FP7-ENV-2011 cod 282957, 261357 and HEALTH.2010.2.4.5-1), Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041; FIS-FEDER: PI041436, PI081151, PI06/0867, PI09/00090, PI13/02187, PI03/1615, PI04/1509, PI04/1112, PI04/1931, PI05/1079, PI05/1052, PI06/1213, PI07/0314, PI09/02647, PI11/01007, PI11/02591, PI11/02038, PI13/1944, PI13/2032, PI14/00891, PI14/01687, PI16/1288 and PI17/00663; Miguel Servet-FEDER CP11/00178, CP15/00025 and CPII16/00051), Generalitat Valenciana: FISABIO (UGP 15-230, UGP-15-244 and UGP-15-249), Alicia Koplowitz Foundation 2017, CIBERESP, Generalitat de Catalunya-CIRIT 1999 SGR 00241, Generalitat de Catalunya-AGAUR 2009 SGR 501, Fundació La marató de TV3 (090430), Department of Health of the Basque Government (2005111093, 2009111069, 2013111089 and 2015111065) and the Provincial Government of Gipuzkoa (DFG06/002, DFG08/001 and DFG15/221). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. The funding sources had no involvement in the study design; the collection, analysis and interpretation of data; or in the writing of the report and the decision to submit the article for publication. Funding information for this article has been deposited with theCrossref Funder Registry.
- ReceivedJanuary 24, 2020.
- Accepted2020年7月23日。
- Copyright ©ERS 2020